30992-66-6

Basic information

• Product Name: 4-HYDROXY-7-BENZYLOXYCOUMARIN
• Synonyms: 4-HYDROXY-7-BENZYLOXYCOUMARIN;4-Hydroxy-7-(phenylMethoxy)-2H-1-benzopyran-2-one;7-(Benzyloxy)-4-hydroxy-couMarin;7-Benzyloxy-4-hydroxycouMarin;7-(Benzyloxy)-4-hydroxy-2H-chromen-2-one;4-hydroxy-7-phenylmethoxychromen-2-one
• CAS NO: 30992-66-6
• Molecular Formula: C₁₆H₁₂O₄
• Molecular Weight: 268.26408
• Product Categories: Aromatics Compounds;Aromatics
• Mol File: 30992-66-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 292-294°C dec.
• Boiling Point: 485.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.363±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4-HYDROXY-7-BENZYLOXYCOUMARIN(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-7-BENZYLOXYCOUMARIN(30992-66-6)
• EPA Substance Registry System: 4-HYDROXY-7-BENZYLOXYCOUMARIN(30992-66-6)

Safety Data

• Hazardous Substances Data: 30992-66-6(Hazardous Substances Data)

Usage

Description

4-Hydroxy-7-benzyloxycoumarin, with the CAS number 30992-66-6, is a pale brown solid compound that plays a significant role in organic synthesis. It is a derivative of coumarin, a class of organic compounds that are characterized by their fused benzene and pyran rings. The presence of a hydroxyl group at the 4-position and a benzyloxy group at the 7-position in its structure contributes to its unique chemical properties and potential applications.

Uses

Used in Organic Synthesis:
4-Hydroxy-7-benzyloxycoumarin is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows it to be a versatile building block for the development of new molecules with potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Hydroxy-7-benzyloxycoumarin is used as a starting material for the synthesis of drug candidates. Its chemical properties enable the formation of new compounds with potential therapeutic effects, making it a valuable asset in the discovery and development of novel medications.
Used in Agrochemical Industry:
4-Hydroxy-7-benzyloxycoumarin is also utilized in the agrochemical industry for the synthesis of bioactive compounds with potential applications as pesticides, herbicides, or insecticides. Its unique structure allows for the development of new molecules with improved efficacy and selectivity, contributing to more sustainable agricultural practices.
Used in Materials Science:
In the field of materials science, 4-Hydroxy-7-benzyloxycoumarin is employed in the synthesis of advanced materials with specific properties. Its chemical structure can be used to create new polymers, coatings, or composites with unique characteristics, such as improved stability, enhanced mechanical properties, or tailored optical properties.

Upstream product

• 1983-81-9 4,7-dihydroxycoumarin 
• 100-39-0 benzyl bromide 
• 29682-12-0 1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone 
• 105-58-8 Diethyl carbonate 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Downstream Products

• 882870-12-4 3-benzyloxy-8,9-dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one 
• 1983-72-8 medicagol 
• 19839-21-5 3-Benzyloxy-5,8,10,12-tetraoxa-benzo[a]cyclopenta[h]fluoren-6-one 
• 1983-81-9 4,7-dihydroxycoumarin 
• 69076-12-6 7-(benzyloxy)-4-hydroxy-3-nitro-2H-chromen-2-one 

Relevant articles and documents

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

AUTOPHAGY INHIBITORS

A compound, which is a) a tetrahydrotriazine derivative of the formula (I), a tautomer, a pharmaceutically acceptable salt, a solvate or hydrate thereof, were the symbols have the meanings given in the description, or b) a coumarin derivative of the formula (II), a tautomer, a pharmaceutically acceptable salt, solvate or hydrate thereof, were the symbols have the meanings given in the description, is useful in a therapeutical method for inhibiting autophagy in a cell and for the treatment of cancer.

Defining a minimum pharmacophore for simocyclinone D8 disruption of DNA gyrase binding to DNA

The increasing occurrence of drug-resistant bacterial infections in the clinic has created a need for new antibacterial agents. Natural products have historically been a rich source of both antibiotics and lead compounds for new antibacterial agents. The natural product simocyclinone D8 (SD8) has been reported to inhibit DNA gyrase, a validated antibacterial drug target, by a unique catalytic inhibition mechanism of action. In this work, we have used a deconstruction-reconstruction approach to prepare analogs of the coumarin subunit of SD8 and evaluated their ability to disrupt binding of the DNA gyrase enzyme to DNA in a surface plasmon resonance assay. This has led to a minimum pharmacophore required for disruption of binding. Springer Science+Business Media 2014.